IL6 and lung carcinoma: Given the crosstalk that occurs between proinflammatory signalling pathways and IL-6, IL-8, and VEGF, as well as the pivotal roles of angiogenic factors in lung cancer, our work may facilitate the design of therapeutic interventions targeting both inflammation and angiogenesis in lung cancer in the future.